Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could sotatercept help PAH patients breathe easier?

NCT ID NCT07140484

Recruiting now Disease control Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug sotatercept can improve how well the lungs transfer oxygen in people with pulmonary arterial hypertension (PAH). Twenty-seven adults with PAH will receive the drug every 21 days for 29 weeks and undergo lung function tests, heart ultrasounds, and blood draws. The goal is to see if the drug helps recruit more lung blood vessels during exercise, which could ease breathing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Familial Primary Pulmonary Hypertension pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERY HYPERTENSION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Physiology Laboratory

    RECRUITING

    Edmonton, Alberta, T6G2R3, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••